USFDA cGMP inspection completed at Cipla's manufacturing facility in Pithampur, Indore

The United States Food and Drug Administration (USFDA) conducted a current Good Manufacturing Practices (cGMP) inspection at Cipla Ltd's Pithampur manufacturing facility from 6th - 17th February, 2023.

On conclusion of the inspection, the Company has received 8 inspectional observations in Form 483. The Company will work closely with the USFDA and is committed to address these comprehensively within stipulated time.

Shares of Cipla Limited was last trading in BSE at Rs. 1025.80 as compared to the previous close of Rs. 1035.80. The total number of shares traded during the day was 26423 in over 1925 trades.

The stock hit an intraday high of Rs. 1035.80 and intraday low of 1021.45. The net turnover during the day was Rs. 27093374.00.

Source : Equity Bulls

Keywords

Cipla INE059A01026 cGMPInspection USFDA Form483 8Observations